Yonhap Infomax News2d ago
Samsung Biologics reports strong Q1 2026 performance with operating profit reaching 580.8 billion won, up 35% year-on-year, while revenue climbed 25.8% to 1.26 trillion won driven by full operation of four plants and Plant 5 ramp-up, maintaining annual growth target of 15-20% set in January.
#YonhapInfomax #SamsungBiologics #Q1OperatingProfit #RevenueGrowth #PlantRampUp #AnnualGrowthTarget #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=116894
Samsung Biologics Q1 Operating Profit Surges to 580.8 Billion Won - Revenue, Operating Profit Both Rise (Update)

Samsung Biologics reports strong Q1 2026 performance with operating profit reaching 580.8 billion won, up 35% year-on-year, while revenue climbed 25.8% to 1.26 trillion won driven by full operation of four plants and Plant 5 ramp-up, maintaining annual growth target of 15-20% set in January.

Yonhap Infomax
Yonhap Infomax News2d ago
Samsung Biologics posts strong first-quarter results with operating profit reaching 580.8 billion won, marking a 35% year-over-year increase as contract manufacturing demand strengthens
#YonhapInfomax #SamsungBiologics #OperatingProfit #FirstQuarter #YearOverYearGrowth #ContractManufacturing #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=116888
Samsung Biologics Q1 Operating Profit Surges 35% to 580.8 Billion Won

Samsung Biologics posts strong first-quarter results with operating profit reaching 580.8 billion won, marking a 35% year-over-year increase as contract manufacturing demand strengthens

Yonhap Infomax
Yonhap Infomax NewsMar 30
Samsung Biologics union votes 95% in favor of first-ever strike over wage dispute, threatening CDMO operations with May 1 walkout as negotiations stall on 14% pay raise demand versus management's 6.2% offer
#YonhapInfomax #SamsungBiologics #LaborStrike #WageNegotiations #CDMOOperations #UnionVote #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=112659
Samsung Biologics Union Announces First-Ever Strike - 95% Approval Rate

Samsung Biologics union votes 95% in favor of first-ever strike over wage dispute, threatening CDMO operations with May 1 walkout as negotiations stall on 14% pay raise demand versus management's 6.2% offer

Yonhap Infomax
General Strike NowMar 30
If no agreement is reached, the union plans to stage a general strike on May 1 at local facilities. If carried out, it would mark the first ...#SamsungBiologics #strike
Samsung Biologics union votes to strike over wage dispute | Yonhap News Agency
Samsung Biologics union votes to strike over wage dispute

SEOUL, March 30 (Yonhap) -- Unionized workers at Samsung Biologics Co. have vote...

Yonhap News Agency
General Strike NowMar 29

If the two sides continue to fail to reach an agreement, the union will begin collective action on May 21, followed by a full general strike on May 1, ...

Samsung Biologics faces its first strike since founding as 95.5% of union voters back walkout, threatening the company's 15 trillion won CDMO expansion strategy amid global competition.#SamsungBiologics #strike #laborunion #CDMO #biopharmaceutical #collectivebargaining #wagenegotiation #SamsungGroup
Samsung Biologics Faces First Strike in 15-Year History

Samsung Biologics Faces First Strike in 15-Year History

Samsung Biologics faces its first strike since founding as 95.5% of union voters back walkout, threatening the company's 15 trillion won CDMO expansion strategy amid global competition.

Seoul Economic Daily
General Strike NowMar 29

The union plans, should the vote approve strike action, to begin collective action on May 21 and escalate to a full-scale general strike on May 1, ...

Samsung Biologics faces its first-ever strike as union members overwhelmingly vote on industrial action after 13 rounds of failed wage negotiations, with workers demanding 14% pay raises amid record earnings.#SamsungBiologics #laborstrike #wagenegotiations #CDMO #biopharmaceutical #unionvote #SamsungGroup #collectivebargaining
Samsung Biologics Faces First-Ever Strike as 95% of Union Members Vote

Samsung Biologics Faces First-Ever Strike as 95% of Union Members Vote

Samsung Biologics faces its first-ever strike as union members overwhelmingly vote on industrial action after 13 rounds of failed wage negotiations, with workers demanding 14% pay raises amid record earnings.

Seoul Economic Daily
Yonhap Infomax NewsMar 23
Samsung Biologics strengthens CDMO competitiveness by internalizing MCB production and vector construction services, enabling nine-month timeline from vector construction to IND submission while enhancing IP protection and reducing development periods through elimination of third-party transfers
#YonhapInfomax #SamsungBiologics #MasterCellBank #VectorConstruction #CDOServices #INDSubmission #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=111389
Samsung Biologics Internalizes MCB Production, Vector Construction to Strengthen CDO Competitiveness

Samsung Biologics strengthens CDMO competitiveness by internalizing MCB production and vector construction services, enabling nine-month timeline from vector construction to IND submission while enhancing IP protection and reducing development periods through elimination of third-party transfers

Yonhap Infomax
Yonhap Infomax NewsMar 20
Samsung Biologics announces 520 billion won capital injection into its U.S. subsidiary to fund acquisition of Human Genome Sciences' biopharmaceutical production facility in Rockville, Maryland, through shareholder allocation with record date set for the 27th.
#YonhapInfomax #SamsungBiologics #CapitalIncrease #HumanGenomeSciences #BiopharmaceuticalFacility #RockvilleFacility #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=111218
Samsung Biologics Injects 520 Billion Won into U.S. Subsidiary Through Capital Increase

Samsung Biologics announces 520 billion won capital injection into its U.S. subsidiary to fund acquisition of Human Genome Sciences' biopharmaceutical production facility in Rockville, Maryland, through shareholder allocation with record date set for the 27th.

Yonhap Infomax
Yonhap Infomax NewsMar 20
Samsung Biologics CEO John Rim, reappointed for a third term, pledges to accelerate expansion in production capacity, portfolio diversification, and global presence despite challenging market conditions, while advancing U.S. plant acquisition and domestic bio campus construction.
#YonhapInfomax #SamsungBiologics #JohnRim #ThreePillarExpansion #ContractManufacturing #GlobalFootprint #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=111123
Samsung Biologics CEO John Rim Secures Third Term, Vows to Accelerate 'Three-Pillar Expansion'

Samsung Biologics CEO John Rim, reappointed for a third term, pledges to accelerate expansion in production capacity, portfolio diversification, and global presence despite challenging market conditions, while advancing U.S. plant acquisition and domestic bio campus construction.

Yonhap Infomax
Yonhap Infomax NewsFeb 9
Bank of Korea urges a national framework to expand bio data access, aiming to boost R&D, address incentive mismatches, and drive growth in South Korea's biohealth sector.
#YonhapInfomax #BankOfKorea #BioData #RDEfficiency #SamsungBiologics #BiohealthMarketGrowth #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=104503